There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTX ...

Song covers the Healthcare sector, focusing on stocks such as Novavax, United Therapeutics, and Viking Therapeutics. According to TipRanks, Song has an average return of -13.6% and a 36.36% success ...

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...

About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the ...

The company's latest presentation supports the idea that its lead program will make billions.